8-K: ZyVersa Therapeutics Issues New Warrants to Induce Exercise of Existing Warrants, Aims for $1.7 Million in Gross Proceeds

ZyVersa Therapeutics is offering new warrants to existing warrant holders to encourage them to exercise their current warrants at a reduced price, potentially raising $1.7 million.

Summary

• ZyVersa Therapeutics is offering new Series A-2 warrants to holders of existing warrants to incentivize them to exercise their current warrants.
• The existing warrants include Series A, Series B, Series A-1, and Series B-1 warrants, which were issued in December 2023 and August 2024.
• The exercise price for the existing warrants is being reduced to $2.06 per share from $12.50 and $3.46 per share.
• In exchange for exercising their existing warrants at the reduced price, holders will receive new Series A-2 warrants to purchase twice the number of shares they acquire through the exercise.
• The new Series A-2 warrants have an exercise price of $2.06 per share and a five-year term from the stockholder approval date.
• If all existing warrants are exercised, ZyVersa expects to receive approximately $1.7 million in gross proceeds.
• The company plans to use the net proceeds for working capital and general corporate purposes.
• The issuance of shares underlying the new warrants is subject to stockholder approval.
• ZyVersa has engaged A.G.P./Alliance Global Partners as a financial advisor for this transaction, paying them a $110,000 cash fee plus up to $10,000 for expenses.

Sentiment

Score: 7

Explanation: The document is generally positive as it outlines a plan to raise capital, but there are risks associated with the dilution of existing shareholders and the need for stockholder approval. The company is taking steps to improve its financial position, which is a positive sign.

Positives

• The warrant inducement offer could provide ZyVersa with approximately $1.7 million in gross proceeds.
• The reduced exercise price may encourage warrant holders to exercise their options, providing immediate capital to the company.
• The new warrants could potentially lead to further capital raising in the future if exercised.
• The company has secured a financial advisor to assist with the transaction.

Negatives

• The company is paying a $110,000 cash fee plus up to $10,000 in expenses to its financial advisor.
• The issuance of new shares upon exercise of the new warrants will dilute existing shareholders.
• The company is relying on stockholder approval for the issuance of the new warrants.

Risks

• There is no guarantee that all existing warrant holders will exercise their warrants.
• The company may not receive the full $1.7 million in gross proceeds if not all warrants are exercised.
• The issuance of new shares could dilute existing shareholders.
• The company is dependent on stockholder approval for the issuance of the new warrants.
• The company is subject to the risk of not meeting the deadlines for filing the registration statement for the resale of the new warrant shares.

Future Outlook

The company intends to use the net proceeds from the warrant exercises for working capital and general corporate purposes. They also plan to file a registration statement for the resale of the new warrant shares and seek stockholder approval for the issuance of the new warrants.

Management Comments

• ZyVersa Therapeutics is pleased to offer this Inducement Offer to you.
• The Company desires to reduce the Exercise Price of the Existing Common Warrants to $2.06 per share of Common Stock.

Industry Context

This type of warrant inducement is a common tactic used by companies to raise capital and improve their balance sheet. It is often used when a company's stock price is below the exercise price of existing warrants, making it less likely that holders will exercise them. By reducing the exercise price and offering new warrants, the company is incentivizing holders to exercise their warrants and provide the company with much needed capital.

Comparison to Industry Standards

• Warrant inducement programs are a fairly common practice for companies seeking to raise capital, particularly in the biotech and pharmaceutical sectors.
• The 200% warrant coverage is a relatively high incentive, which may be necessary to encourage participation given the significant reduction in exercise price.
• The use of a financial advisor like A.G.P. is standard practice for these types of transactions, ensuring compliance and market expertise.
• The timeline for filing the registration statement and obtaining stockholder approval is typical for such transactions.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Warrant holders are given an opportunity to exercise their warrants at a reduced price and receive new warrants.
• The company may improve its financial position through the capital raise.
• Employees may benefit from the company's improved financial stability.

Next Steps

• The company will need to obtain stockholder approval for the issuance of the new warrants.
• The company will file a registration statement on Form S-3 for the resale of the new warrant shares by December 20, 2024.
• The company will need to ensure the new warrants are issued and delivered to the holders.
• The company will need to manage the potential dilution of existing shareholders.

Key Dates

Keywords

warrants, exercise, inducement, capital raise, common stock, financial advisory, dilution, stockholder approval